Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States.
It operates through two segments, Therapeutics and Contract Research.
The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
The Contract Research segment offers laboratory services.
The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis.
It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer.
Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 6, 24 | -0.24 Increased by +40.00% | -0.29 Increased by +17.24% |
| Feb 27, 24 | -0.02 Increased by +95.12% | -0.34 Increased by +94.12% |
| Nov 6, 23 | -0.41 Decreased by -36.67% | -0.48 Increased by +14.58% |
| Aug 7, 23 | -0.42 Decreased by -35.48% | -0.45 Increased by +6.67% |
| May 8, 23 | -0.40 Decreased by -29.03% | -0.44 Increased by +9.09% |
| Feb 23, 23 | -0.41 Decreased by -10.81% | -0.45 Increased by +8.89% |
| Nov 8, 22 | -0.30 Increased by +14.29% | -0.40 Increased by +25.00% |
| Aug 3, 22 | -0.31 Increased by +8.82% | -0.36 Increased by +13.89% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.28 M Decreased by -51.19% | -29.26 M Decreased by -37.83% | Decreased by -315.24% Decreased by -182.40% |
| Jun 30, 23 | 1.87 M Increased by +22.32% | -29.57 M Decreased by -77.38% | Decreased by -1.58 K% Decreased by -45.02% |
| Mar 31, 23 | 2.53 M Increased by +73.98% | -26.40 M Decreased by -51.12% | Decreased by -1.04 K% Increased by +13.14% |
| Dec 31, 22 | 7.75 M Increased by +416.52% | -33.29 M Decreased by -45.99% | Decreased by -429.40% Increased by +71.74% |
| Sep 30, 22 | 19.02 M Increased by +1.05 K% | -21.23 M Decreased by -0.40% | Decreased by -111.63% Increased by +91.24% |
| Jun 30, 22 | 1.53 M Decreased by -16.23% | -16.67 M Increased by +8.21% | Decreased by -1.09 K% Decreased by -9.57% |
| Mar 31, 22 | 1.45 M Decreased by -18.23% | -17.47 M Increased by +39.24% | Decreased by -1.20 K% Increased by +25.69% |
| Dec 31, 21 | 1.50 M Decreased by -5.00% | -22.80 M Decreased by -73.11% | Decreased by -1.52 K% Decreased by -82.22% |